Rituximab is usually effective in patients with membranous nephropathy, but there may be some patients who are not sensitive to the drug and have poor efficacy, so it is necessary to look at the actual condition. Compared with the traditional treatment program, rituximab treatment of membranous nephropathy has gained a certain degree of clinical application in terms of efficacy and safety. Rituximab is a human-mouse chimeric monoclonal antibody that specifically binds to the transmembrane antigen CD20 and has immunosuppressive effects. It is indicated for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and membranous nephropathy. The main adverse reactions of rituximab are anemia, thrombocytopenia, bacterial infection, viral infection, and angioedema. The product is contraindicated in hypersensitivity to its components and allergy to murine proteins. Note that the use of rituximab requires attention to monitor the occurrence of infusion reactions, as well as the occurrence of tumor lysis syndrome, etc.. The overall remission rate of patients treated with rituximab in combination with other non-immunosuppressive agents is increased, and rituximab treatment for membranous nephropathy also has greater advantages in long-term remission and reduction of recurrence. Patients with membranous nephropathy can use rituximab carefully after evaluation by physicians. It is recommended that patients with membranous nephropathy should consult a doctor in time and follow the doctor’s instructions.